FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280564937> ?p ?o ?g. }

• W4280564937 abstract "Platelet factor 4 (PF4) or the CXC chemokine CXCL4 is the most abundant protein within the α-granules of platelets. Previous studies found that PF4 regulates infections of several viruses, including HIV-1, H1N1, hepatitis C virus (HCV), and dengue virus. Here, we show that PF4 is an inhibitor of enterovirus A71 (EV71) and coxsackievirus A16 (CA16) infections. The secreted form of PF4 from transfected cells or soluble purified PF4 from Escherichia coli, even lacking signal peptide affected secretion, obviously inhibited the propagation of EV71 and CA16. Mechanistically, we demonstrated that PF4 blocked the entry of the virus into the host cells by interactions with VP3 proteins of EV71/CA16 and the interaction with SCARB2 receptor-mediated EV71 and CA16 endocytosis. As expected, the incubation of anti-PF4 antibody with PF4 blocked PF4 inhibition on EV71 and CA16 infections further supported the above conclusion. Importantly, pretreatment of EV71 viruses with PF4 significantly protected the neonatal mice from EV71 lethal challenge and promoted the survival rate of infected mice. PF4 derived from natural platelets by EV71/CA16 activation also presented strong inhibition on EV71 and CA16. In summary, our study identified a new host factor against EV71 and CA16 infections, providing a novel strategy for EV71 and CA16 treatment. IMPORTANCE The virus's life cycle starts with binding to cell surface receptors, resulting in receptor-mediated endocytosis. Targeting the entry of the virus into target cells is an effective strategy to develop a novel drug. EV71 and CA16 are the major pathogens that cause hand, foot, and mouth disease (HFMD) outbreaks worldwide since 2008. However, the treatment of EV71 and CA16 infections is mainly symptomatic because there is no approved drug. Therefore, the underlying pathogenesis of EV71/CA16 and the interaction between host-EV71/CA16 need to be further investigated to develop an inhibitor. Here, we identified PF4 as a potent entry inhibitor of EV71 and CA16 via binding to VP3 proteins of EV71 and CA16 or binding to receptor SCARB2. In the EV71 infection model, PF4 protected mice from EV71 lethal challenge and promoted the survival rate of EV71-infected mice. Our study suggests that PF4 represents a potential candidate host factor for anti-EV71 and CA16 infections." @default.
• W4280564937 created "2022-05-22" @default.
• W4280564937 creator A5020478594 @default.
• W4280564937 creator A5031682624 @default.
• W4280564937 creator A5033020983 @default.
• W4280564937 creator A5072488525 @default.
• W4280564937 creator A5076768386 @default.
• W4280564937 creator A5078632164 @default.
• W4280564937 date "2022-06-08" @default.
• W4280564937 modified "2023-09-25" @default.
• W4280564937 title "Chemokine PF4 Inhibits EV71 and CA16 Infections at the Entry Stage" @default.
• W4280564937 cites W1503223519 @default.
• W4280564937 cites W1967780926 @default.
• W4280564937 cites W1976954262 @default.
• W4280564937 cites W1981011310 @default.
• W4280564937 cites W2000491192 @default.
• W4280564937 cites W2001371234 @default.
• W4280564937 cites W2016236015 @default.
• W4280564937 cites W2038314679 @default.
• W4280564937 cites W2044775356 @default.
• W4280564937 cites W2052741717 @default.
• W4280564937 cites W2080485793 @default.
• W4280564937 cites W2088824727 @default.
• W4280564937 cites W2091150362 @default.
• W4280564937 cites W2126687348 @default.
• W4280564937 cites W2129238955 @default.
• W4280564937 cites W2133846188 @default.
• W4280564937 cites W2134094618 @default.
• W4280564937 cites W2146023328 @default.
• W4280564937 cites W2155657787 @default.
• W4280564937 cites W2160359084 @default.
• W4280564937 cites W2216915854 @default.
• W4280564937 cites W2257731750 @default.
• W4280564937 cites W2540522966 @default.
• W4280564937 cites W2580326307 @default.
• W4280564937 cites W2583681475 @default.
• W4280564937 cites W2612987103 @default.
• W4280564937 cites W2794356724 @default.
• W4280564937 cites W2796452931 @default.
• W4280564937 cites W2902339840 @default.
• W4280564937 cites W2902868601 @default.
• W4280564937 cites W2982426951 @default.
• W4280564937 cites W3007704142 @default.
• W4280564937 cites W3008919653 @default.
• W4280564937 cites W3091465752 @default.
• W4280564937 cites W3109164254 @default.
• W4280564937 cites W3125833749 @default.
• W4280564937 cites W4210612718 @default.
• W4280564937 cites W3035178128 @default.
• W4280564937 doi "https://doi.org/10.1128/jvi.00435-22" @default.
• W4280564937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35579435" @default.
• W4280564937 hasPublicationYear "2022" @default.
• W4280564937 type Work @default.
• W4280564937 citedByCount "6" @default.
• W4280564937 countsByYear W42805649372022 @default.
• W4280564937 countsByYear W42805649372023 @default.
• W4280564937 crossrefType "journal-article" @default.
• W4280564937 hasAuthorship W4280564937A5020478594 @default.
• W4280564937 hasAuthorship W4280564937A5031682624 @default.
• W4280564937 hasAuthorship W4280564937A5033020983 @default.
• W4280564937 hasAuthorship W4280564937A5072488525 @default.
• W4280564937 hasAuthorship W4280564937A5076768386 @default.
• W4280564937 hasAuthorship W4280564937A5078632164 @default.
• W4280564937 hasBestOaLocation W42805649372 @default.
• W4280564937 hasConcept C13373296 @default.
• W4280564937 hasConcept C140704245 @default.
• W4280564937 hasConcept C159047783 @default.
• W4280564937 hasConcept C159973064 @default.
• W4280564937 hasConcept C170493617 @default.
• W4280564937 hasConcept C203014093 @default.
• W4280564937 hasConcept C2522874641 @default.
• W4280564937 hasConcept C2777888124 @default.
• W4280564937 hasConcept C2778889330 @default.
• W4280564937 hasConcept C28005876 @default.
• W4280564937 hasConcept C55493867 @default.
• W4280564937 hasConcept C58475186 @default.
• W4280564937 hasConcept C86803240 @default.
• W4280564937 hasConcept C89560881 @default.
• W4280564937 hasConceptScore W4280564937C13373296 @default.
• W4280564937 hasConceptScore W4280564937C140704245 @default.
• W4280564937 hasConceptScore W4280564937C159047783 @default.
• W4280564937 hasConceptScore W4280564937C159973064 @default.
• W4280564937 hasConceptScore W4280564937C170493617 @default.
• W4280564937 hasConceptScore W4280564937C203014093 @default.
• W4280564937 hasConceptScore W4280564937C2522874641 @default.
• W4280564937 hasConceptScore W4280564937C2777888124 @default.
• W4280564937 hasConceptScore W4280564937C2778889330 @default.
• W4280564937 hasConceptScore W4280564937C28005876 @default.
• W4280564937 hasConceptScore W4280564937C55493867 @default.
• W4280564937 hasConceptScore W4280564937C58475186 @default.
• W4280564937 hasConceptScore W4280564937C86803240 @default.
• W4280564937 hasConceptScore W4280564937C89560881 @default.
• W4280564937 hasFunder F4320327282 @default.
• W4280564937 hasFunder F4320327720 @default.
• W4280564937 hasFunder F4320328832 @default.
• W4280564937 hasIssue "11" @default.
• W4280564937 hasLocation W42805649371 @default.
• W4280564937 hasLocation W42805649372 @default.
• W4280564937 hasLocation W42805649373 @default.
• W4280564937 hasOpenAccess W4280564937 @default.

• next